SCHEMBL4876798

SCHEMBL4876798

NC(Cc1ccccc1)C1CCC2(CC1)OCCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
EPHX1 P07099 1/20 0.39
C5AR1 P21730 3/20 0.38
ALPI P09923 1/20 0.38
PKM P14618 1/20 0.38
PTGS1 P23219 1/20 0.38
XIAP P98170 1/20 0.38
SLC7A5 Q01650 1/20 0.38
SLC6A2 P23975 2/20 0.37
TAAR1 Q96RJ0 2/20 0.37
MAOA P21397 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CYP2A6 P11509 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
DPP4 P27487 2/20 0.36
DPP9 Q86TI2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044565 0.82 MEN1 (0.44) MEN1KMT2AC5AR1TP53ALDH1A1
SCHEMBL2469254 0.80 EPHX1 (0.54) EPHX1ALPIPKMPTGS1XIAP
Ammonia Solution, Strong SCHEMBL16268928 0.78 EPHX1 (0.52) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL1735295 0.77 EPHX1 (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL3285405 0.77 EPHX1 (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL1735316 0.77 EPHX1 (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL23581390 0.76 SIGMAR1 (0.43) MEN1KMT2AC5AR1TAAR1SIGMAR1
SCHEMBL3289204 0.75 DPP4 (0.49) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL10716724 0.75 DPP4 (0.49) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL27478385 0.72 DPP4 (0.51) EPHX1SLC6A2TAAR1MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE MEN1 3980/4885KMT2A 1759/4885EPHX1 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.